See more : Prime Electronics & Satellitics Inc. (6152.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Hyundai Pharmaceutical Co., Ltd. (004310.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hyundai Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- TAI-TECH Advanced Electronics Co., Ltd. (3357.TWO) Income Statement Analysis – Financial Results
- Meganet Corporation (MGNT) Income Statement Analysis – Financial Results
- HolidayCheck Group AG (0G8Z.L) Income Statement Analysis – Financial Results
- NetImpact Holdings, Inc. (NTHD) Income Statement Analysis – Financial Results
- Cadeler A/S (CADLF) Income Statement Analysis – Financial Results
Hyundai Pharmaceutical Co., Ltd. (004310.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hyundaipharm.co.kr
About Hyundai Pharmaceutical Co., Ltd.
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical equipment in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and eye vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. The company was founded in 1965 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 180.76B | 162.69B | 139.80B | 132.97B | 134.65B | 130.79B | 130.48B | 120.02B | 109.83B | 107.84B | 108.14B | 102.25B | 113.05B | 111.86B | 122.88B | 120.52B | 111.66B |
| Cost of Revenue | 105.52B | 93.85B | 83.49B | 74.64B | 70.97B | 70.32B | 68.50B | 72.88B | 67.55B | 66.31B | 67.42B | 62.98B | 66.26B | 64.02B | 71.60B | 67.12B | 56.33B |
| Gross Profit | 75.24B | 68.84B | 56.31B | 58.32B | 63.68B | 60.47B | 61.98B | 47.14B | 42.28B | 41.53B | 40.71B | 39.27B | 46.78B | 47.84B | 51.28B | 53.40B | 55.33B |
| Gross Profit Ratio | 41.62% | 42.31% | 40.28% | 43.86% | 47.30% | 46.23% | 47.50% | 39.27% | 38.49% | 38.51% | 37.65% | 38.40% | 41.38% | 42.77% | 41.73% | 44.31% | 49.55% |
| Research & Development | 11.97B | 8.38B | 8.09B | 9.62B | 11.81B | 13.59B | 13.13B | 6.00M | 66.81M | 39.67M | 67.69M | 391.59M | 158.89M | 659.63M | 1.81B | 3.73B | 4.18B |
| General & Administrative | 10.39B | 10.11B | 10.97B | 9.68B | 10.92B | 10.90B | 10.94B | 10.45B | 10.01B | 10.09B | 9.67B | 11.69B | 10.39B | 11.60B | 11.17B | 9.87B | 8.89B |
| Selling & Marketing | 20.67B | 18.07B | 11.96B | 10.58B | 12.81B | 12.97B | 12.68B | 13.40B | 10.99B | 10.24B | 9.25B | 9.77B | 9.42B | 14.04B | 14.99B | 13.24B | 15.48B |
| SG&A | 31.07B | 28.18B | 22.94B | 20.26B | 23.74B | 23.87B | 23.62B | 23.85B | 21.00B | 20.33B | 18.92B | 21.46B | 19.81B | 25.64B | 26.17B | 23.11B | 24.37B |
| Other Expenses | 25.28B | 24.32B | 26.86B | 25.39B | 26.09B | 26.15M | -798.95M | -725.05M | -928.01M | -254.07M | -962.21M | -1.08B | -2.02B | -2.01B | -1.16B | -1.25B | -638.86M |
| Operating Expenses | 68.31B | 60.87B | 57.88B | 55.27B | 61.64B | 63.13B | 59.97B | 44.81B | 40.57B | 39.28B | 38.52B | 43.59B | 43.03B | 46.76B | 48.32B | 49.16B | 48.53B |
| Cost & Expenses | 173.84B | 154.72B | 141.37B | 129.91B | 132.61B | 133.45B | 128.47B | 117.69B | 108.12B | 105.58B | 105.95B | 106.57B | 109.30B | 110.77B | 119.92B | 116.28B | 104.86B |
| Interest Income | 742.87M | 392.90M | 49.86M | 46.84M | 35.11M | 69.49M | 24.00M | 116.14M | 113.35M | 285.08M | 392.25M | 402.69M | 554.97M | 437.34M | 701.74M | 1.09B | 1.56B |
| Interest Expense | 1.91B | 1.16B | 712.77M | 614.07M | 678.28M | 727.20M | 844.64M | 604.34M | 556.34M | 683.88M | 973.72M | 1.27B | 1.12B | 1.27B | 1.21B | 737.58M | 0.00 |
| Depreciation & Amortization | 3.30B | 3.30B | 3.98B | 4.11B | 3.51B | 3.20B | 2.75B | 2.24B | 1.96B | 1.91B | 2.11B | 2.36B | 2.27B | 2.29B | 2.60B | 2.63B | 2.30B |
| EBITDA | 13.21B | 10.04B | 273.16M | 7.34B | 5.58B | 726.44M | 1.79B | 4.33B | 7.53B | 4.20B | 4.24B | -2.59B | 5.75B | 2.22B | 5.74B | 7.19B | 9.11B |
| EBITDA Ratio | 7.31% | 6.24% | 2.27% | 5.58% | 5.18% | 0.59% | 3.01% | 3.51% | 2.80% | 3.90% | 3.90% | -2.32% | 4.29% | 1.98% | 5.38% | 3.50% | 3.02% |
| Operating Income | 6.93B | 7.97B | -811.83M | 3.05B | 3.47B | -2.66B | 2.01B | 2.33B | 1.71B | 2.25B | 2.19B | -4.32B | 3.75B | 1.09B | 2.96B | 4.24B | 6.80B |
| Operating Income Ratio | 3.83% | 4.90% | -0.58% | 2.30% | 2.58% | -2.03% | 1.54% | 1.94% | 1.55% | 2.09% | 2.02% | -4.22% | 3.32% | 0.97% | 2.41% | 3.52% | 6.09% |
| Total Other Income/Expenses | 1.11B | -2.30B | -2.45B | -370.01M | -519.79M | -473.13M | -827.83M | -982.92M | 3.33B | -644.92M | -1.04B | -1.90B | -1.39B | 2.71B | -1.04B | -415.56M | 6.50B |
| Income Before Tax | 8.03B | 5.67B | -4.02B | 2.68B | 1.52B | -3.13B | 1.57B | 1.35B | 5.03B | 1.61B | 1.15B | -6.21B | 2.36B | 3.79B | 1.92B | 3.83B | 13.30B |
| Income Before Tax Ratio | 4.44% | 3.48% | -2.88% | 2.02% | 1.13% | -2.39% | 1.21% | 1.12% | 4.58% | 1.49% | 1.06% | -6.08% | 2.09% | 3.39% | 1.56% | 3.17% | 11.91% |
| Income Tax Expense | 1.91B | 5.83B | -847.54M | 495.80M | 310.20M | -1.02B | 116.27M | 86.60M | 3.44B | 139.83M | -308.81M | -1.37B | 1.37B | 825.86M | 248.73M | 350.42M | 3.57B |
| Net Income | 6.12B | -164.58M | -3.17B | 2.19B | 1.21B | -2.11B | 1.46B | 1.26B | 1.59B | 1.47B | 1.41B | -4.85B | 989.55M | 2.97B | 1.67B | 3.48B | 9.74B |
| Net Income Ratio | 3.39% | -0.10% | -2.27% | 1.64% | 0.90% | -1.61% | 1.12% | 1.05% | 1.45% | 1.36% | 1.31% | -4.74% | 0.88% | 2.65% | 1.36% | 2.88% | 8.72% |
| EPS | 225.81 | -5.92 | -113.82 | 79.91 | 44.49 | -76.00 | -69.00 | 55.52 | 66.24 | 61.37 | 58.45 | -201.64 | 40.91 | 120.79 | 66.24 | 127.61 | 343.47 |
| EPS Diluted | 225.81 | -5.92 | -113.82 | 79.91 | 44.49 | -76.00 | -69.00 | 55.52 | 66.24 | 61.37 | 58.45 | -201.64 | 40.91 | 120.79 | 66.24 | 127.61 | 343.47 |
| Weighted Avg Shares Out | 27.11M | 27.81M | 27.88M | 27.37M | 27.26M | 27.72M | 23.71M | 25.07M | 24.06M | 23.92M | 24.07M | 24.05M | 24.19M | 24.57M | 25.22M | 27.23M | 28.35M |
| Weighted Avg Shares Out (Dil) | 27.11M | 27.81M | 27.88M | 27.37M | 27.26M | 27.72M | 23.79M | 25.16M | 24.06M | 23.92M | 24.07M | 24.05M | 24.19M | 24.57M | 25.22M | 27.23M | 28.35M |
Source: https://incomestatements.info
Category: Stock Reports